BACKGROUND: Guillain-Barre syndrome (GBS) is considered an acute immune-mediated monophasic illness. Standard therapy includes intravenous immunoglobulin (IVIG) and/or plasmapheresis. Yet, long-standing disability remains a problem. In Indonesia, the availability and cost of these therapies are constraints. AIM: To show the capability of hyperbaric oxygen (HBO2) therapy in GBS patients who did not undergo standard therapy. HBO2 also provides healing in patients who experience delays in therapy. METHODS: Data included identity, demographic, social history, current disease history, disease progression and therapies used. Data were displayed in the form of tables and graphs. RESULTS: Twenty-five GBS patients underwent HBO2 from 2016 to 2019. The majority of patients were males aged 20-30 years, triggered by preceding diarrhea. After approximately three to ten days following HBO2, they felt their first positive changes. They walked with assistance after two to three weeks receiving HBO2 and without assistance after four to 12 weeks receiving HBO2. CONCLUSION: HBO2 administration show clinical improvement in GBS patients. HBO2 is expected to become an adjuctive therapy for GBS patients in Indonesia.

Original languageEnglish
Pages (from-to)1174-1179
Number of pages6
JournalOpen Access Macedonian Journal of Medical Sciences
Publication statusPublished - 26 Dec 2021


  • Characteristics
  • Guillain-Barre syndrome
  • Hyperbaric oxygen therapy


Dive into the research topics of 'Characteristics of guillain-barre syndrome patient underwent hyperbaric oxygen therapy at lakesla 2016–2019'. Together they form a unique fingerprint.

Cite this